Financial reports
ARS
2023 FY
Annual report to shareholders
22 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
ARS
2022 FY
Annual report to shareholders
23 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
Current reports
8-K
Regulation FD Disclosure
25 Apr 24
8-K
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
28 Mar 24
8-K
Regulation FD Disclosure
13 Feb 24
8-K
Other Events
4 Jan 24
8-K
Other Events
21 Dec 23
8-K
Regulation FD Disclosure
19 Dec 23
8-K
Regulation FD Disclosure
28 Nov 23
8-K
Entry into a Material Definitive Agreement
1 Nov 23
8-K
Other Events
16 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
3 Jul 23
Registration and prospectus
S-3
Shelf registration
7 Mar 24
S-8
Registration of securities for employees
7 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 24
S-8
Registration of securities for employees
3 Nov 23
S-8
Registration of securities for employees
9 Mar 23
S-8
Registration of securities for employees
17 Mar 22
424B5
Prospectus supplement for primary offering
29 Apr 21
424B5
Prospectus supplement for primary offering
27 Apr 21
S-3
Shelf registration
11 Mar 21
S-8
Registration of securities for employees
11 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
DEF 14A
Definitive proxy
23 May 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
DEFA14A
Additional proxy soliciting materials
22 Apr 19
Other
EFFECT
Notice of effectiveness
25 Apr 24
EFFECT
Notice of effectiveness
16 Apr 21
CORRESP
Correspondence with SEC
13 Apr 21
UPLOAD
Letter from SEC
17 Mar 21
CT ORDER
Confidential treatment order
4 Oct 18
EFFECT
Notice of effectiveness
27 Jul 18
UPLOAD
Letter from SEC
26 Jul 18
CORRESP
Correspondence with SEC
25 Jul 18
EFFECT
Notice of effectiveness
19 Jan 17
EFFECT
Notice of effectiveness
19 Jan 17
Ownership
4/A
Stephen Machatha
17 Apr 24
4/A
Bruce Greenberg
17 Apr 24
4
JOSEPH EDELMAN
8 Apr 24
4
JOSEPH EDELMAN
3 Apr 24
4
Bruce Greenberg
12 Mar 24
4
Stephen Machatha
12 Mar 24
4
Todd C Brady
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24